{"id":15037,"date":"2022-09-01T07:00:24","date_gmt":"2022-09-01T05:00:24","guid":{"rendered":"https:\/\/www.sequanamedical.com\/?p=15037"},"modified":"2022-08-31T15:37:37","modified_gmt":"2022-08-31T13:37:37","slug":"sequana-medical-notice-of-2022-half-year-results-and-business-update","status":"publish","type":"post","link":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-notice-of-2022-half-year-results-and-business-update\/","title":{"rendered":"Sequana Medical Notice of 2022 Half Year Results and Business Update"},"content":{"rendered":"<p><strong>Ghent, Belgium \u2013 1 September 2022 \u2013 <\/strong><strong>Sequana Medical NV (Euronext Brussels: SEQUA) <\/strong>(the &#8220;<strong>Company<\/strong>&#8221; or &#8220;<strong>Sequana<\/strong> <strong>Medical<\/strong>&#8220;), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, will announce its half year results ended 30 June 2022 on Thursday, 8 September 2022.<\/p>\n<p>The management team will host a conference call with live webcast at 03:00 pm CET \/ 09:00 am EST on the day of the results.<\/p>\n<p>The webcast can be accessed by registering on the <a href=\"\/?page_id=5536\">Investors eventpage<\/a> of Sequana Medical\u2019s website or by clicking <a href=\"https:\/\/channel.royalcast.com\/landingpage\/sequanamedical\/20220908_1\/\">here<\/a>. To participate in the Q&amp;A, please click <a href=\"https:\/\/event.loopup.com\/SelfRegistration\/registration.aspx?booking=yv2aZjQzCKDFMszD4SbmUOJd5BLWpu7l6YQm3YIAh2I=&amp;b=528f7d33-d6cf-439e-b143-56d7da6b8e57\">here<\/a> to register. Once registered, you will receive dial-in numbers and a confirmation code. The webcast and conference call will be conducted in English and a replay will be available on the Company\u2019s <a href=\"\/?page_id=5536\">website<\/a> shortly thereafter.<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>For more information, please contact: <\/strong><\/p>\n<p><strong>Sequana Medical<\/strong><\/p>\n<table>\n<tbody>\n<tr>\n<td width=\"327\"><strong>For EU investors:<\/strong><\/td>\n<td width=\"327\"><strong>For US investors:<\/strong><\/td>\n<\/tr>\n<tr>\n<td width=\"327\">Lies Vanneste<\/td>\n<td width=\"327\">Amy Sullivan<\/td>\n<\/tr>\n<tr>\n<td width=\"327\">Director Investor Relations<\/td>\n<td width=\"327\">Consultant to Sequana Medical<\/td>\n<\/tr>\n<tr>\n<td width=\"327\">Email: <a href=\"mailto:IR@sequanamedical.com\">IR@sequanamedical.com<\/a><\/td>\n<td width=\"327\">Email: <a href=\"mailto:amy.sullivan@sequanamedical.com\">amy.sullivan@sequanamedical.com<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"327\">Tel: +32 498 05 35 79<\/td>\n<td width=\"327\"><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>Optimum Strategic Communications<\/strong><\/p>\n<table>\n<tbody>\n<tr>\n<td width=\"327\"><strong>For media:<\/strong><\/td>\n<\/tr>\n<tr>\n<td width=\"327\">Nick Bastin, Rebecca Noonan<\/td>\n<\/tr>\n<tr>\n<td width=\"327\">Tel: +44 (0) 20 3922 0900<\/td>\n<\/tr>\n<tr>\n<td width=\"327\">Email: <a href=\"mailto:Sequana@optimumcomms.com\">Sequana@optimumcomms.com<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>About Sequana Medical<\/strong><\/p>\n<p>Sequana Medical NV is a pioneer in treating drug-resistant fluid overload, a serious and frequent clinical complication in patients with liver disease, heart failure and cancer. Fluid overload is a well-recognized problem in these growing diseases, causing severe problems for the large number of patients for whom current medicines are no longer effective. These patients can have up to 15 liters of extra fluid in their bodies, causing major medical issues including increased mortality, repeated hospitalizations, severe pain, difficult breathing and restricted mobility that severely impacts daily life.<\/p>\n<p><strong>alfa<\/strong>pump\u00ae and DSR\u00ae are Sequana Medical\u2019s proprietary platforms that work with the body to remove this excess fluid, delivering major clinical and quality of life benefits for patients and reducing costs for healthcare systems. Sequana Medical is listed on Euronext Brussels (Ticker: SEQUA.BR) and headquartered in Ghent, Belgium. For further information, please visit <a href=\"https:\/\/www.sequanamedical.com\">www.sequanamedical.com<\/a>.<\/p>\n<p><strong><em>\u00a0<\/em><\/strong><\/p>\n<p><strong><em>Important Regulatory Disclaimers<\/em><\/strong><\/p>\n<p><em>The\u00a0<strong>alfa<\/strong>pump\u00ae system is currently not approved in the United States or Canada. In the United States and Canada, the\u00a0<strong>alfa<\/strong>pump system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see\u00a0<\/em><a href=\"https:\/\/www.poseidonstudy.com\/\"><em>www.poseidonstudy.com<\/em><\/a><em>. DSR\u00ae therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. DSR therapy is currently not approved for clinical research in the United States or Canada. There is no link between DSR therapy and ongoing investigations with the\u00a0<strong>alfa<\/strong>pump system in Europe, the United States or Canada. <\/em><\/p>\n<p><strong><em>Note:<\/em><\/strong><em> <strong>alfa<\/strong>pump\u00ae is a registered trademark. DSR\u00ae and <strong>alfa<\/strong>pump DSR\u00ae are registered trademarks in the Benelux, China, the EU, United Kingdom, and Hong Kong.<\/em><\/p>\n<p><strong><em>\u00a0<\/em><\/strong><\/p>\n<p><strong><em>Forward-looking statements<\/em><\/strong><\/p>\n<p><em>This press release may contain predictions, estimates or other information that might be considered forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements represent the current judgment of Sequana Medical on what the future holds, and are subject to risks and uncertainties that could cause actual results to differ materially. Sequana Medical expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release, except if specifically required to do so by law or regulation. You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release.<\/em><\/p>\n<p><strong>\u00a0<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ghent, Belgium \u2013 1 September 2022 \u2013 Sequana Medical NV (Euronext Brussels: SEQUA) (the &#8220;Company&#8221; or &#8220;Sequana Medical&#8220;), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, will announce its half year results ended 30 June 2022 on Thursday, 8 September 2022. The management team will host a [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[74],"tags":[94],"class_list":["post-15037","post","type-post","status-publish","format-standard","hentry","category-persberichten","tag-niet-gereglementeerd"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sequana Medical Notice of 2022 Half Year Results and Business Update - Sequana Medical<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-notice-of-2022-half-year-results-and-business-update\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sequana Medical Notice of 2022 Half Year Results and Business Update - Sequana Medical\" \/>\n<meta property=\"og:description\" content=\"Ghent, Belgium \u2013 1 September 2022 \u2013 Sequana Medical NV (Euronext Brussels: SEQUA) (the &#8220;Company&#8221; or &#8220;Sequana Medical&#8220;), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, will announce its half year results ended 30 June 2022 on Thursday, 8 September 2022. The management team will host a [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-notice-of-2022-half-year-results-and-business-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Sequana Medical\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/alfapump\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-01T05:00:24+00:00\" \/>\n<meta name=\"author\" content=\"Lies Vanneste\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@SequanaMed\" \/>\n<meta name=\"twitter:site\" content=\"@SequanaMed\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-notice-of-2022-half-year-results-and-business-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-notice-of-2022-half-year-results-and-business-update\\\/\"},\"author\":{\"name\":\"Lies Vanneste\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#\\\/schema\\\/person\\\/d19e52ba140d6e8fc2907b3b460e8ac3\"},\"headline\":\"Sequana Medical Notice of 2022 Half Year Results and Business Update\",\"datePublished\":\"2022-09-01T05:00:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-notice-of-2022-half-year-results-and-business-update\\\/\"},\"wordCount\":600,\"publisher\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#organization\"},\"keywords\":[\"Niet-gereglementeerd\"],\"articleSection\":[\"Persberichten\"],\"inLanguage\":\"nl-NL\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-notice-of-2022-half-year-results-and-business-update\\\/\",\"url\":\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-notice-of-2022-half-year-results-and-business-update\\\/\",\"name\":\"Sequana Medical Notice of 2022 Half Year Results and Business Update - Sequana Medical\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#website\"},\"datePublished\":\"2022-09-01T05:00:24+00:00\",\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-notice-of-2022-half-year-results-and-business-update\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#website\",\"url\":\"https:\\\/\\\/www.sequanamedical.com\\\/\",\"name\":\"Sequana Medical\",\"description\":\"Pioneer in the treatment of fluid overload\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sequanamedical.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#organization\",\"name\":\"Sequana Medical NV\",\"url\":\"https:\\\/\\\/www.sequanamedical.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sequanamedical.com\\\/wp-content\\\/uploads\\\/2017\\\/09\\\/Sequana-medical_logo.png\",\"contentUrl\":\"https:\\\/\\\/www.sequanamedical.com\\\/wp-content\\\/uploads\\\/2017\\\/09\\\/Sequana-medical_logo.png\",\"width\":396,\"height\":70,\"caption\":\"Sequana Medical NV\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/alfapump\",\"https:\\\/\\\/x.com\\\/SequanaMed\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/sequana-medical\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#\\\/schema\\\/person\\\/d19e52ba140d6e8fc2907b3b460e8ac3\",\"name\":\"Lies Vanneste\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6f62aa1d55dc8a8289dd18faa628d22e5c34f8d569432403cd0bee21b4875095?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6f62aa1d55dc8a8289dd18faa628d22e5c34f8d569432403cd0bee21b4875095?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6f62aa1d55dc8a8289dd18faa628d22e5c34f8d569432403cd0bee21b4875095?s=96&d=mm&r=g\",\"caption\":\"Lies Vanneste\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sequana Medical Notice of 2022 Half Year Results and Business Update - Sequana Medical","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-notice-of-2022-half-year-results-and-business-update\/","og_locale":"nl_NL","og_type":"article","og_title":"Sequana Medical Notice of 2022 Half Year Results and Business Update - Sequana Medical","og_description":"Ghent, Belgium \u2013 1 September 2022 \u2013 Sequana Medical NV (Euronext Brussels: SEQUA) (the &#8220;Company&#8221; or &#8220;Sequana Medical&#8220;), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, will announce its half year results ended 30 June 2022 on Thursday, 8 September 2022. The management team will host a [&hellip;]","og_url":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-notice-of-2022-half-year-results-and-business-update\/","og_site_name":"Sequana Medical","article_publisher":"https:\/\/www.facebook.com\/alfapump","article_published_time":"2022-09-01T05:00:24+00:00","author":"Lies Vanneste","twitter_card":"summary_large_image","twitter_creator":"@SequanaMed","twitter_site":"@SequanaMed","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-notice-of-2022-half-year-results-and-business-update\/#article","isPartOf":{"@id":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-notice-of-2022-half-year-results-and-business-update\/"},"author":{"name":"Lies Vanneste","@id":"https:\/\/www.sequanamedical.com\/#\/schema\/person\/d19e52ba140d6e8fc2907b3b460e8ac3"},"headline":"Sequana Medical Notice of 2022 Half Year Results and Business Update","datePublished":"2022-09-01T05:00:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-notice-of-2022-half-year-results-and-business-update\/"},"wordCount":600,"publisher":{"@id":"https:\/\/www.sequanamedical.com\/#organization"},"keywords":["Niet-gereglementeerd"],"articleSection":["Persberichten"],"inLanguage":"nl-NL"},{"@type":"WebPage","@id":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-notice-of-2022-half-year-results-and-business-update\/","url":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-notice-of-2022-half-year-results-and-business-update\/","name":"Sequana Medical Notice of 2022 Half Year Results and Business Update - Sequana Medical","isPartOf":{"@id":"https:\/\/www.sequanamedical.com\/#website"},"datePublished":"2022-09-01T05:00:24+00:00","inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-notice-of-2022-half-year-results-and-business-update\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.sequanamedical.com\/#website","url":"https:\/\/www.sequanamedical.com\/","name":"Sequana Medical","description":"Pioneer in the treatment of fluid overload","publisher":{"@id":"https:\/\/www.sequanamedical.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sequanamedical.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/www.sequanamedical.com\/#organization","name":"Sequana Medical NV","url":"https:\/\/www.sequanamedical.com\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/www.sequanamedical.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.sequanamedical.com\/wp-content\/uploads\/2017\/09\/Sequana-medical_logo.png","contentUrl":"https:\/\/www.sequanamedical.com\/wp-content\/uploads\/2017\/09\/Sequana-medical_logo.png","width":396,"height":70,"caption":"Sequana Medical NV"},"image":{"@id":"https:\/\/www.sequanamedical.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/alfapump","https:\/\/x.com\/SequanaMed","https:\/\/www.linkedin.com\/company\/sequana-medical"]},{"@type":"Person","@id":"https:\/\/www.sequanamedical.com\/#\/schema\/person\/d19e52ba140d6e8fc2907b3b460e8ac3","name":"Lies Vanneste","image":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/secure.gravatar.com\/avatar\/6f62aa1d55dc8a8289dd18faa628d22e5c34f8d569432403cd0bee21b4875095?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/6f62aa1d55dc8a8289dd18faa628d22e5c34f8d569432403cd0bee21b4875095?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6f62aa1d55dc8a8289dd18faa628d22e5c34f8d569432403cd0bee21b4875095?s=96&d=mm&r=g","caption":"Lies Vanneste"}}]}},"_links":{"self":[{"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/posts\/15037","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/comments?post=15037"}],"version-history":[{"count":0,"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/posts\/15037\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/media?parent=15037"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/categories?post=15037"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/tags?post=15037"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}